FMP
Regulus Therapeutics Inc.
RGLS
NASDAQ
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
1.59 USD
0.04 (2.52%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Joseph P. Hagan M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.regulusrx.comexchange
NASDAQ
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headq...
CIK
0001505512
ISIN
US75915K3095
CUSIP
75915K309
Address
4224 Campus Point Court
Phone
858 202 6300
Country
US
Employee
32
IPO Date
Oct 9, 2012
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
RGLS Financial Summary
CIK
0001505512
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
75915K309
ISIN
US75915K3095
Country
US
Price
1.59
Beta
1.63
Volume Avg.
337.7k
Market Cap
104.15M
Shares
-
52-Week
1.08-3.79
DCF
1.13
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.56
P/B
-
Website
https://www.regulusrx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RGLS News
It looks like there's no news available.
